by Lori Solomon The U.S. Food and Drug Administration has approved UCB’ Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis. Zilbrysq is a targeted peptide inhibitor of complement component 5 (C5) and is approved as a once-daily, self-administered, targeted therapy in patients with anti-acetylcholine receptor (AChR)-antibody-positive generalized myasthenia gravis. The approval of...
